Alz&Deme:一种现有药物或能预防阿尔兹海默症

2018-08-10 佚名 中国生物技术网

一项新研究表明,一种“强效”药能预防阿尔兹海默症的发生,但前提是,只有在症状发生之前很长时间服用这种药物才有效果。

一项新研究表明,一种“强效”药能预防阿尔兹海默症的发生,但前提是,只有在症状发生之前很长时间服用这种药物才有效果。

阿尔兹海默症是最常见的痴呆症。截止到2017年,全球大约有2430万阿尔兹海默症患者,每年新发病例460万。据估计,2050 年全球每85 个人中将有1 人是阿尔兹海默症患者, 阿尔兹海默症已成为全球公共卫生的一个严重威胁。

但非常不幸的是,目前没有治疗阿尔兹海默症的有效方法,在疾病发生之后,症状往往会逐渐恶化。这就带来了一个问题,那些被认为阿尔兹海默症风险高的人到底能否预防这种疾病?

美国弗吉尼亚大学的这项新研究表明,一种名为美金刚(memantine,目前用于控制阿尔兹海默症症状)的药物其实可以预防该疾病。然而,只有在阿尔兹海默症症状出现之前很长时间服用这种药物才有效果。

弗吉尼亚大学的George Bloom教授说:“根据我们迄今为止所学到的,我认为,一旦患者的阿尔兹海默症症状出现,我们就永远没有办法治愈它了。征服这种疾病最大的希望是首次识别出高风险人群,并使用新药来进行预防,也许生活方式的调整也能够延长该疾病进程的静默阶段。最理想的情况是,我们可以在未开始的时候就防止该疾病发生。”该研究近日已发表在《Alzheimer's & Dementia》期刊上。

研究人员解释称,其实在症状出现很早之前(或许10年以上)阿尔兹海默症就已经发生了。该疾病的一个特征是,一旦患病,试图分裂的脑细胞(也许是为了平衡其他神经元的死亡)却只会死亡。

在任何情况下,健康的大脑中,完全成形的脑细胞是不会再进一步分裂的。这些受影响的神经元尝试分裂的行为被称为“细胞周期重入进程”。

Bloom教授解释说:“据估计,阿尔兹海默症发生时,大约90%的神经元死亡都与细胞周期重入进程,这是一种不正常的分裂尝试。在疾病后期,患者大脑额叶会损失大约30%的神经元。”

研究第一作者Erin Kodis是Bloom教授的博士生,她提出了关于触发这一机制的假设。她认为,过量的钙会通过细胞表面的NMDA受体进入神经元。这会促使脑细胞开始分裂。

经过一系列实验之后,Kodis证实她的假说是正确的。在淀粉样蛋白斑块形成之前这一机制就已经启动了,大脑中的淀粉样蛋白斑块是阿尔兹海默症的特征。

最终,β淀粉样蛋白的氨基酸分子会聚集到一起形成有毒的淀粉样斑块。

美金刚或具有“强力疗效”

Kodis发现,当神经元在斑块积聚之前的早期阶段遇到β淀粉样蛋白分子时,NMDA受体会开放地接受过量的钙,而这最终导致细胞破坏。

但随后研究人员们取得了另一项发现:美金刚这种药物能通过关闭神经元表面的NMDA受体来阻止细胞周期重入进程。

George Bloom教授说:“这些实验表明,如果在患者出现阿尔兹海默症症状或确诊之前很久开始服用美金刚,那么它能起到有效的疾病预防作用。”

Bloom教授补充说:“也许这种药能预防疾病或者延缓疾病的进程,使阿尔兹海默症的发病时间显著延后。”

这些发现非常具有前景,美金刚几乎没有已知的副作用,而且已报道的副作用很少,并且对个体的健康没有重大影响。

Bloom教授相信,在未来,一种有效的预防方法可以用于筛查高风险人群,在阿尔兹海默症发生之前及早地发现疾病迹象。

Bloom说,如果这样的话,医生们就可以为患阿尔兹海默症风险高的患者开出美金刚处方。人们可能不得不终身服用这种药物来预防阿尔兹海默症。

Bloom教授说:“我不想为人们带来虚假的希望。如果美金刚的预防作用有效的话,那是因为我们现在理解了钙是导致这种疾病开始的因素之一,如果我们及早采取行动的话,就可以预防或者延缓该疾病的进程。”

目前,Bloom和同事们正在计划一项临床试验来测试该药物的预防作用。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=338199, encodeId=436f33819905, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sun Aug 12 22:19:56 CST 2018, time=2018-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338137, encodeId=b45933813e9d, content=太好了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK6QdulvyRKvs4FAIXXUItgUibicpFKh4ODnBVO0rQshLkkmxS2DwneVpFiannyyWOTA8ekpHNIPZR8w/132, createdBy=8ae12052879, createdName=牛肉帕尼尼, createdTime=Sun Aug 12 14:33:51 CST 2018, time=2018-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402763, encodeId=83621402e634d, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Sun Aug 12 06:26:00 CST 2018, time=2018-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337885, encodeId=c08c33e885da, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Sat Aug 11 10:20:19 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337803, encodeId=1dff33e803ed, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sat Aug 11 00:41:02 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337725, encodeId=017b33e72569, content=还需研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5171668917, createdName=坚强007, createdTime=Fri Aug 10 16:52:27 CST 2018, time=2018-08-10, status=1, ipAttribution=)]
    2018-08-12 1ddf0692m34(暂无匿称)

    学习了,谢谢分享

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=338199, encodeId=436f33819905, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sun Aug 12 22:19:56 CST 2018, time=2018-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338137, encodeId=b45933813e9d, content=太好了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK6QdulvyRKvs4FAIXXUItgUibicpFKh4ODnBVO0rQshLkkmxS2DwneVpFiannyyWOTA8ekpHNIPZR8w/132, createdBy=8ae12052879, createdName=牛肉帕尼尼, createdTime=Sun Aug 12 14:33:51 CST 2018, time=2018-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402763, encodeId=83621402e634d, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Sun Aug 12 06:26:00 CST 2018, time=2018-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337885, encodeId=c08c33e885da, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Sat Aug 11 10:20:19 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337803, encodeId=1dff33e803ed, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sat Aug 11 00:41:02 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337725, encodeId=017b33e72569, content=还需研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5171668917, createdName=坚强007, createdTime=Fri Aug 10 16:52:27 CST 2018, time=2018-08-10, status=1, ipAttribution=)]
    2018-08-12 牛肉帕尼尼

    太好了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=338199, encodeId=436f33819905, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sun Aug 12 22:19:56 CST 2018, time=2018-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338137, encodeId=b45933813e9d, content=太好了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK6QdulvyRKvs4FAIXXUItgUibicpFKh4ODnBVO0rQshLkkmxS2DwneVpFiannyyWOTA8ekpHNIPZR8w/132, createdBy=8ae12052879, createdName=牛肉帕尼尼, createdTime=Sun Aug 12 14:33:51 CST 2018, time=2018-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402763, encodeId=83621402e634d, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Sun Aug 12 06:26:00 CST 2018, time=2018-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337885, encodeId=c08c33e885da, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Sat Aug 11 10:20:19 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337803, encodeId=1dff33e803ed, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sat Aug 11 00:41:02 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337725, encodeId=017b33e72569, content=还需研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5171668917, createdName=坚强007, createdTime=Fri Aug 10 16:52:27 CST 2018, time=2018-08-10, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=338199, encodeId=436f33819905, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sun Aug 12 22:19:56 CST 2018, time=2018-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338137, encodeId=b45933813e9d, content=太好了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK6QdulvyRKvs4FAIXXUItgUibicpFKh4ODnBVO0rQshLkkmxS2DwneVpFiannyyWOTA8ekpHNIPZR8w/132, createdBy=8ae12052879, createdName=牛肉帕尼尼, createdTime=Sun Aug 12 14:33:51 CST 2018, time=2018-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402763, encodeId=83621402e634d, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Sun Aug 12 06:26:00 CST 2018, time=2018-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337885, encodeId=c08c33e885da, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Sat Aug 11 10:20:19 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337803, encodeId=1dff33e803ed, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sat Aug 11 00:41:02 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337725, encodeId=017b33e72569, content=还需研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5171668917, createdName=坚强007, createdTime=Fri Aug 10 16:52:27 CST 2018, time=2018-08-10, status=1, ipAttribution=)]
    2018-08-11 明月清辉

    谢谢分享,学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=338199, encodeId=436f33819905, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sun Aug 12 22:19:56 CST 2018, time=2018-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338137, encodeId=b45933813e9d, content=太好了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK6QdulvyRKvs4FAIXXUItgUibicpFKh4ODnBVO0rQshLkkmxS2DwneVpFiannyyWOTA8ekpHNIPZR8w/132, createdBy=8ae12052879, createdName=牛肉帕尼尼, createdTime=Sun Aug 12 14:33:51 CST 2018, time=2018-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402763, encodeId=83621402e634d, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Sun Aug 12 06:26:00 CST 2018, time=2018-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337885, encodeId=c08c33e885da, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Sat Aug 11 10:20:19 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337803, encodeId=1dff33e803ed, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sat Aug 11 00:41:02 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337725, encodeId=017b33e72569, content=还需研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5171668917, createdName=坚强007, createdTime=Fri Aug 10 16:52:27 CST 2018, time=2018-08-10, status=1, ipAttribution=)]
    2018-08-11 kafei

    学习了谢谢

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=338199, encodeId=436f33819905, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sun Aug 12 22:19:56 CST 2018, time=2018-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338137, encodeId=b45933813e9d, content=太好了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK6QdulvyRKvs4FAIXXUItgUibicpFKh4ODnBVO0rQshLkkmxS2DwneVpFiannyyWOTA8ekpHNIPZR8w/132, createdBy=8ae12052879, createdName=牛肉帕尼尼, createdTime=Sun Aug 12 14:33:51 CST 2018, time=2018-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402763, encodeId=83621402e634d, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Sun Aug 12 06:26:00 CST 2018, time=2018-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337885, encodeId=c08c33e885da, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Sat Aug 11 10:20:19 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337803, encodeId=1dff33e803ed, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sat Aug 11 00:41:02 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337725, encodeId=017b33e72569, content=还需研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5171668917, createdName=坚强007, createdTime=Fri Aug 10 16:52:27 CST 2018, time=2018-08-10, status=1, ipAttribution=)]
    2018-08-10 坚强007

    还需研究

    0

相关资讯

患阿尔茨海默病的风险会受肝脏、饮食的影响

阿尔茨海默病是一种最常见的老年痴呆疾病。主要表现为渐进性记忆障碍、认知功能障碍等症状,严重影响社交及生活功能。患阿尔茨海默病的风险受多种因素的影响,本周在阿尔茨海默症协会国际会议(AAIC)上的一项新研究显示,患阿尔茨海默病的风险还与肝脏及饮食有关。

Alzheimers Dement:“重新定义”阿尔兹海默症?科学家建议,按照生物标志物来!

4月10日,Alzheimer’s & Dementi协会发布一份报告建议,“重新定义”阿尔兹海默症,即根据大脑的变化,而不是记忆衰退等认知症状定义这一疾病。这一改变有望建立“通用语言”,加快药物研发以及诊疗方案的及早干预。

Nat Chem:研究人员发现胆固醇或催化阿尔茨海默病

研究人员在由 7 日出版的 《自然·化学》 刊载的论文中写道:“我们现在的问题不是要消除大脑中的胆固醇,而是需要通过调节胆固醇与贝塔淀粉状蛋白的相互作用来控制它对阿尔茨海默病的作用。我们不能说胆固醇是(贝塔淀粉状蛋白)积聚的唯一催化剂,但肯定是之一。”

Journal of Neuroinflammation:酒精或可增加阿尔兹海默症风险

这一研究发表在《Journal of Neuroinflammation》期刊,科学家们发现,酒精会影响小鼠大脑中小胶质细胞的基因,从而干扰其吞噬、清理淀粉样蛋白(阿尔兹海默症典型的致病蛋白,会在大脑中过度累积形成老年斑,最终损伤神经元)的过程。

希望!阿尔茨海默病新药2期临床全新出炉,减缓认知衰退效果显著

开发治疗阿尔茨海默症的药物一直是条艰辛之路,因此,即使是取得一点点的成功也会让人兴奋。近日,由卫材(Eisai)与百健(Biogen)合作开发的阿兹海默病新药BAN2401“惊喜亮相”于阿尔茨海默症协会国际会议上。这一半年前还不被看好的药物带着出色的2期临床数据引起医药圈和媒体广泛关注。

vTv Therapeutics公司阿尔茨海默症候选药物临床试验失败

阿尔兹海默症是一种神经系统退行性疾病,自2003年批准美金刚以来,15年都没有新药面世。大量基础研究表明晚期糖基化终产物受体(RAGE)可能参与调控阿尔茨海默症中淀粉样蛋白的累积、脑部炎症以及慢性神经元功能的丧失,vTv Therapeutics公司针对该靶点投入近18年的心血开发了小分子拮抗剂Azrainragon。